Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation			$ 1,091,517	$ 746,342
Employee and director stock option grants
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 367,759	$ 421,161	1,091,517	746,342
Employee and director stock option grants \| Research and development
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	37,211	62,655	123,638	133,450
Employee and director stock option grants \| General and administrative
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 330,548	$ 358,506	$ 967,879	$ 612,892